SCHEMBL11160737

SCHEMBL11160737

COc1c(O)cc2c(c1Sc1ccccc1)CCN(C)CC2

nearest known ligand 0.73

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DRD1 P21728 9/20 0.43
▸ DRD2 P14416 8/20 0.43
▸ DRD5 P21918 5/20 0.43
▸ DRD3 P35462 3/20 0.43
▸ HTR2A P28223 1/20 0.41
▸ DRD4 P21917 1/20 0.41
▸ MAPK1 P28482 1/20 0.39
▸ THPO P40225 1/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ MTOR P42345 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ PMP22 Q01453 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11160967 0.86 DRD1 (0.47) DRD1DRD2DRD5DRD3HTR2A
SCHEMBL10471907 0.84 DRD1 (0.44) DRD1DRD2DRD5DRD3DRD4
Bromide SCHEMBL11159318 0.83 DRD1 (0.47) DRD1DRD2DRD5DRD3DRD4
SCHEMBL11171000 0.82 DRD1 (0.38) DRD1DRD2DRD5DRD3DRD4
Fumaric Acid SCHEMBL11169294 0.81 MEN1 (0.43) DRD1DRD2DRD5DRD3DRD4
Fumaric Acid SCHEMBL11169280 0.81 MEN1 (0.43) DRD1DRD2DRD5DRD3DRD4
SCHEMBL11160741 0.79 SMN1; SMN2 (0.38) DRD1DRD2DRD5DRD3DRD4
SCHEMBL11160867 0.79 DRD1 (0.43) DRD1DRD2DRD5DRD3DRD4
SCHEMBL10700283 0.79 DRD1 (0.49) DRD1DRD2DRD5DRD3DRD4
Hydrochloric Acid SCHEMBL10703949 0.78 DRD1 (0.48) DRD1DRD2DRD5DRD3DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0007070-B1 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS HAVING DOPAMINE RECEPTOR BLOCKING ACTIVITY SMITHKLINE BECKMAN CORPORATION (US) 1983-01-19 — — EP claimed
US-4265890-A ANTIPSYCHOTIC, ANTIEMETICS SMITHKLINE CORPORATION (US) 1981-05-05 — — US claimed
EP-0007070-A1 2,3,4,5-Tetrahydro-1H-3-Benzazepines, process for their production and pharmaceutical compositions having dopamine receptor blocking activity SMITHKLINE BECKMAN CORPORATION (US) 1980-01-23 — — EP claimed
EP-0080012-A1 6-Chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its acid addition salts and its use as an intermediate SMITHKLINE BECKMAN CORPORATION (US) 1983-06-01 — — EP disclosed
EP-0007070-B1 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS HAVING DOPAMINE RECEPTOR BLOCKING ACTIVITY SMITHKLINE BECKMAN CORPORATION (US) 1983-01-19 — — EP disclosed
US-4265890-A ANTIPSYCHOTIC, ANTIEMETICS SMITHKLINE CORPORATION (US) 1981-05-05 — — US disclosed
EP-0007070-A1 2,3,4,5-Tetrahydro-1H-3-Benzazepines, process for their production and pharmaceutical compositions having dopamine receptor blocking activity SMITHKLINE BECKMAN CORPORATION (US) 1980-01-23 — — EP disclosed
Send feedback